Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

The results demonstrate that compared to avutometinib alone, the FAK inhibitor/avutometinib combination inhibits RAS/MAPK pathway signaling more deeply while also blocking key adaptive resistance ...

Fintel reports that on March 26, 2025, Raymond James initiated coverage of Erasca (NasdaqGS:ERAS) with a Outperform ...

A new review was published in , Volume 16, on March 13, 2025, titled "Signaling pathway dysregulation in breast cancer." ...

Innovations in therapeutic strategies, coupled with a deeper understanding of breast cancer biology, will be essential for advancing personalized ...

Intech Investment Management LLC increased its holdings in shares of Erasca, Inc. (NASDAQ:ERAS – Free Report) by 53.9% during ...

Perion Network Ltd. , a leader in advanced technology solving for the complexities of modern advertising, announced today the filing of its annual report on Form 20-F for the fiscal year ended ...

HC Wainwright issued their FY2029 earnings estimates for Erasca in a report issued on Friday, March 21st. HC Wainwright ...

Eli Lilly and Company today announced that preclinical data for agents targeting SMARCA2 (BRM) and multiple KRAS mutations will be presented at the American Association for Cancer Research (AACR) ...

Despite the high incidence of brain metastasis after resection of non-small cell lung cancer (NSCLC), the National Comprehensive Cancer Network guidelines do not recommend central nervous system (CNS) ...

The fifth and latest scheme to assist working families and renters to transition into homeownership has been launched.